现代生物科学公司开发了XAFTY®,这是一种用于COVID-19,mopox和登革热的3期试验中的广泛抗病毒药物. Hyundai Bioscience develops XAFTY®, a broad-spectrum antiviral drug in Phase 3 trials for COVID-19, mpox, and dengue.
现代生物科学公司开发了XAFTY®,一种针对COVID-19,mopox和登革热的广泛抗病毒药物. Hyundai Bioscience has developed XAFTY®, a broad-spectrum antiviral drug targeting COVID-19, mpox, and dengue. 在费城疾病预防和控制峰会(2024年)上,该公司报告说,XAFTYETYETH来自硝酸盐,目前正在对COVID-19进行第三阶段试验,重点是高危病人。 At the Disease Prevention and Control Summit 2024 in Philadelphia, the company reported that XAFTY® is derived from niclosamide and is currently in Phase 3 trials for COVID-19, focusing on high-risk patients. 该药物对 mpox 和登革热的有效性尤其显着，这些疾病没有现有的治疗方法，并且正在进行讨论以加快其可用性。 The drug is particularly notable for its effectiveness against mpox and dengue, conditions with no existing treatments, and discussions are ongoing to expedite its availability.